Disease-modifying Antirheumatic Agents

Name
Disease-modifying Antirheumatic Agents
Accession Number
DBCAT003604
Description

Not Available

Drugs
DrugDrug Description
EtanerceptA protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis.
AnakinraA recombinant form of human interleukin-1 receptor antagonist used in the treatment of rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and deficiency of interleukin-1 receptor antagonist (DIRA).
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
LeflunomideA pyrimidine synthesis inhibitor indicated to treat rheumatoid arthritis.
AbataceptA disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
ApremilastA non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
GolimumabA TNF╬▒ inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
TofacitinibA Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
UpadacitinibAn oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.
BaricitinibA Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist.
Drugs & Drug Targets
DrugTargetType
EtanerceptTumor necrosis factortarget
EtanerceptLymphotoxin-alphatarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
EtanerceptComplement component 1q (C1q)target
AnakinraInterleukin-1 receptor type 1target
AdalimumabTumor necrosis factortarget
InfliximabTumor necrosis factortarget
LeflunomideDihydroorotate dehydrogenase (quinone), mitochondrialtarget
LeflunomideCytochrome P450 1A2enzyme
LeflunomideCytochrome P450 2C9enzyme
LeflunomideAryl hydrocarbon receptortarget
LeflunomideProtein-tyrosine kinase 2-betatarget
LeflunomideATP-binding cassette sub-family G member 2transporter
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
AbataceptCytotoxic T-lymphocyte protein 4target
ApremilastPhosphodiesterase isozyme 4target
ApremilastCytochrome P450 3A4enzyme
ApremilastCytochrome P450 2A6enzyme
ApremilastCytochrome P450 1A2enzyme
ApremilastP-glycoprotein 1transporter
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
GolimumabTumor necrosis factortarget
TofacitinibNon-receptor tyrosine-protein kinase TYK2target
TofacitinibCytochrome P450 3A4enzyme
TofacitinibCytochrome P450 2C19enzyme
TofacitinibTyrosine-protein kinase JAK2target
TofacitinibTyrosine-protein kinase JAK1target
TofacitinibTyrosine-protein kinase JAK3target
TofacitinibSerum albumincarrier
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
UpadacitinibTyrosine-protein kinase JAK1target
UpadacitinibCytochrome P450 3A4enzyme
UpadacitinibCytochrome P450 2D6enzyme
UpadacitinibP-glycoprotein 1transporter
UpadacitinibATP-binding cassette sub-family G member 2transporter
UpadacitinibSolute carrier organic anion transporter family member 1B1transporter
BaricitinibSolute carrier family 22 member 8transporter
BaricitinibATP-binding cassette sub-family G member 2transporter
BaricitinibMultidrug and toxin extrusion protein 2transporter
BaricitinibCytochrome P450 3A4enzyme
BaricitinibTyrosine-protein kinase JAK1target
BaricitinibTyrosine-protein kinase JAK2target
BaricitinibSolute carrier family 22 member 6transporter
BaricitinibSolute carrier family 22 member 2transporter
BaricitinibSolute carrier organic anion transporter family member 1B3transporter
BaricitinibTyrosine-protein kinase JAK3target
BaricitinibP-glycoprotein 1transporter
BaricitinibNon-receptor tyrosine-protein kinase TYK2target